MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/87.5/0.1/20.09.24 | Market Closed - Börse Stuttgart 11:50:02 14/06/2024 pm IST | ||
| 0.11 EUR | -0.90% |
|
| Current month | +19.57% | ||
| 1 month | +19.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 14/24/14 | 0.11 | -0.90% |
| 13/24/13 | 0.111 | -11.20% |
| 12/24/12 | 0.125 | +15.74% |
| 11/24/11 | 0.108 | -16.92% |
| 10/24/10 | 0.13 | +4.84% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 11:50 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | ME1FUM |
| ISIN | DE000ME1FUM9 |
| Date issued | 03/10/2023 |
| Strike | 87.5 $ |
| Maturity | 20/09/2024 (96 Days) |
| Parity | 10 : 1 |
| Emission price | 0.17 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.166 € |
|---|---|
| Lowest since issue | 0.005 € |
| Spread | 0.003 € |
| Spread % | 2.56% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.6
USD
Average target price
174.4
USD
Spread / Average Target
+9.95%
- Stock Market
- Warrants
- Warrant
